USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: CLEVELAND LEUKEMIA THERAPEUTICS, LLC
Address: 11000 CEDAR AVE
CLEVELAND, OH 44106-3069
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $542,351.00 3

Award List:

Identifying Small Molecule Inhibitors of HdmX using Cell-based Screening

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mukesh K. Agarwal
Award Amount: $188,748.00
Abstract:
DESCRIPTION (provided by applicant): Loss of the p53 signaling pathway, either by mutation or loss of upstream or downstream signaling components, occurs in the vast majority of human cancers. In normal cells, Hdm2 and HdmX coordinately regulate the stabil ity and function of p53. However, each… More

A novel ellipticine analog as a therapeutic candidate for acute myeloid leukemia

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mukesh K. Agarwal
Award Amount: $153,770.00
Abstract:
DESCRIPTION (provided by applicant): Existing therapeutic agents for Acute Myeloid Leukemia (AML) are inadequate to due poor efficacy and severe side effects. This is especially a problem in adults where the 5 year survival is less than 20-50%. Differentai tion therapy for AML holds significant… More

TAS::75 0849::TAS TOPIC 255 DEVELOPMENT OF A TARGETED THERAPY FOR ACUTE MYELOID

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mukesh Agarwal – 216-789-6000
Award Amount: $199,833.00
Abstract:
Acute myeloid leukemia (AML) is one of the most common forms of leukemia in adults and despite advances in treatment the 5 year survival is less than 20-50% in adults and significantly lower in the elderly. The remarkable success in treating one relatively uncommon subset of AML, acute… More